
Robert Lloyd Ruxer Jr. MD FACP
Hematologic Oncology, Hospice & Palliative
Physician
Join to view full profile
500 S Henderson StSte 200Fort Worth, TX 76104
Phone+1 817-413-1500
Fax+1 817-413-1499
Dr. Ruxer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 1981 - 1983
Wright-Patterson Medical CenterResidency, Internal Medicine, 1978 - 1981
Virginia Commonwealth University School of MedicineClass of 1978
Certifications & Licensure
TX State Medical License 1994 - 2027
MD State Medical License 1981 - 1995
OH State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Publications & Presentations
PubMed
- 40 citationsA Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal ...Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sideris, Nghia Nguyen
Clinical Colorectal Cancer. 2016-12-01 - 154 citationsRandomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior ChemotherapySamir E. Witta, Robert M. Jotte, Katrik Konduri, Marcus A. Neubauer, Alexander I. Spira
Journal of Clinical Oncology. 2012-04-16 - 22 citationsPemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.Mark A. Socinski, Robert N. Raju, Marcus A. Neubauer, David Smith, Donald A. Richards
Journal of Thoracic Oncology. 2008-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: